Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Kolkata has experienced a severe outbreak of cough and cold, affecting thousands with sore throats and temporary voice loss. Doctors warn of prolonged symptoms due to fluctuating temperatures and ...

A new purple box graces the parish hall of Christ Church Cooperstown. It contains boxes of naloxone — brand name Narcan — ...

The city has installed Narcan kits at public locations after receiving them as a donation from Mothers for Awareness and ...

Dr. Syed Hussain from Trinity Health of New England discusses the latest health news from around the country and the world.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

School nurses, teachers or other people trained and qualified would be authorized to administer the nasal spray to a student or staff member experiencing symptoms of an opioid overdose.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...